

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION

To: ING. BARZANO' & ZANARDO MILANO S.P.A. Attn. Coppo, Alessandro Via Borgonuovo, 10 I-20121 Milan ITALY	ING. B. & Z. Milano 11 LUG. 2005
--	-------------------------------------

(PCT Rule 44.1)

Date of mailing (day/month/year)	08/07/2005
-------------------------------------	------------

Applicant's or agent's file reference Ndp-89345	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No. PCT/IB2005/000544	International filing date (day/month/year) 01/03/2005
Applicant GIULIANI S.P.A.	

1. The applicant is hereby notified that the International search report and the written opinion of the International Searching Authority have been established and are transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes
1211 Geneva 20, Switzerland, Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. The applicant is hereby notified that no International search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.

3. With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

- the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
- no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. Reminders

Shortly after the expiration of 18 months from the priority date, the International application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90b/s.1 and 90b/s.3, respectively, before the completion of the technical preparations for International publication.

The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an International preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.

Within 19 months from the priority date, but only in respect of some designated Offices, a demand for International preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the *PCT Applicant's Guide*, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the International Searching Authority European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Tanja Rührmund
--	--

Re Item V.

- 1 Reference is made to the following documents:
D1 : JP-A-10 017456 (see also EPODOC abstract and JP machine translation)
D2 : K. SHIMIZU ET AL.: "Steroid 5alpha-Reductase Inhibitory Activity and Hair Regrowth Effects of an Extract from Boehmeria nippononivea"
BIOSCI.BIOTECHNOL.BIOCHEM., vol. 64, no. 4, 2000, pages 875-877
D3 : US-A-6 017 893
D4 : WO-A-01/52840
D5 : WO-A-94/05250
- 2 The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of Claims 1, 8 - 16 is not new in the sense of Article 33(2) PCT.
- 2.1 Document D1 discloses a composition for regulating the trophism of hair follicles comprising an extract of Boehmeria such as Boehmeria nippononivea and antioxidants (see D1: claims, passages 004, 006, 012, 016). The compositions can be prepared as topical and oral (drug/quasi-drug) compositions.
- 3 Even if the Applicant were able to establish novelty of the claims with respect to document D1, the present application does not meet the criteria of Article 33(1) PCT, because the subject matter of claim 1 does not involve an inventive step in the sense of Article 33(3)PCT.
- 3.1 Document D1 or D2 (see D2: page 877, left hand column), which are both considered to represent the most relevant state of the art to the subject matter of Claim 1, discloses compositions for regulating the trophism of hair follicles (stimulating hair growth, action against acne, seborrhoea, hirsutism) comprising an extract of Boehmeria nippononivea.
- 3.2 The subject-matter of independent Claim 1 differs from the disclosure of D1/D2 in that the compositions further comprise a sulfur donor compound or a eg. flavonoid antioxidant.

3.3 The Applicant has not demonstrated that this difference leads to any technical effect. The statement in the application that the extract of *Boehmeria nipponivea* and the sulfur donor compound or flavonoid antioxidant exhibit a synergistic effect has not been backed up by evidence. The examples on file either comprise only the extract of *Boehmeria nipponivea* (composition A) or a composition comprising *Boehmeria nipponivea* and isoflavones (composition B) or a placebo (composition C). These examples only demonstrate an effect with respect to the compositions only comprising the extract of *Boehmeria nipponivea*. However, they are not suitable to show any synergism (ie **non additive** effect).

3.4 The problem to be solved by the present invention may therefore only be regarded as the provision of further compositions for regulating the trophism of hair follicles, acting against acne, seborrhoea, hirsutism etc. comprising an extract of *Boehmeria nipponivea*.

3.5 In view of D3 - D5 the solution proposed in Claim 1 of the present application cannot be considered as involving an inventive step (Article 33(3) PCT) because sulfur donor compounds such as cysteine, cystine, methionine or antioxidants such as isoflavones are known in the art D3 - D5 as valuable additives for hair treatment compositions.

3.6 A skilled person aiming at solving the above mentioned problem (see 3.4. above) would combine, without exercise of any inventive skills in order to solve the problem posed, the compounds such as cysteine, cystine, methionine or antioxidants such as isoflavones with the compositions of D1/D2. The mere arbitrary choice (and addition) from the host of possible compounds known from the prior art to the compositions of D1/D2 is not considered as involving an inventive step. In order to be inventive the choice must be purposive, ie. justified by a technical effect not known in the prior art. The proposed solution in independent Claim 1 thus cannot be considered inventive (Article 33(3) PCT).

4 Claims 2-16

Dependent claims 2-16 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of novelty and/or inventive step (Article 33(2) and (3) PCT).

5 First/second medical use

5.1 Claims 9 - 11 are drafted as first medical use claims. However, as stated under item 2. the medical use of compositions comprising an extract of Boehmeria nippononivea is known in the art. Consequently, Claims drafted in the form of a first medical use are not any more allowable.

5.2 Claims 13 - 16 are directed to a food supplement (to a product). A product however, cannot be characterized (ie limited) by its intended use, but only by its composition. Consequently, Claims 13 - 16 are identical in scope. The form of Claims 13 - 16 as first medical use claims is in any case not allowable. A possible form of claims 13 - 16 would be a use claim.

6 The expression "sulfur donor compound" used in the Claims is considered unclear in the sense of Art. 6 PCT. The only compounds supported by the description are those mentioned on page 7, lines 3 - 7, in particular cystine, cysteine and methionine.

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/IB2005/000544

Box No. I Basis of the opinion

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
 - a. type of material:
 a sequence listing
 table(s) related to the sequence listing
 - b. format of material:
 in written format
 in computer readable form
 - c. time of filing/furnishing:
 contained in the international application as filed.
 filed together with the international application in computer readable form.
 furnished subsequently to this Authority for the purposes of search.
3. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the International application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.